 Cindy O'Bryant
Concepts (315)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 21 | 2024 | 2060 | 1.870 |
Why?
| | Neoplasms | 31 | 2024 | 2475 | 1.730 |
Why?
| | Antiemetics | 2 | 2024 | 39 | 0.880 |
Why?
| | Pyridines | 5 | 2015 | 477 | 0.860 |
Why?
| | Piperidines | 3 | 2021 | 190 | 0.830 |
Why?
| | Indazoles | 1 | 2021 | 66 | 0.720 |
Why?
| | Anilides | 2 | 2013 | 73 | 0.710 |
Why?
| | Liver | 3 | 2021 | 1833 | 0.700 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 31 | 0.660 |
Why?
| | Immunoconjugates | 2 | 2023 | 102 | 0.650 |
Why?
| | Cisplatin | 5 | 2024 | 298 | 0.640 |
Why?
| | Morpholines | 1 | 2020 | 125 | 0.630 |
Why?
| | Drug Hypersensitivity | 1 | 2020 | 82 | 0.610 |
Why?
| | Drug Interactions | 6 | 2024 | 360 | 0.570 |
Why?
| | Pharmacists | 4 | 2017 | 264 | 0.560 |
Why?
| | Protein Kinase Inhibitors | 5 | 2024 | 872 | 0.550 |
Why?
| | Carcinoma, Basal Cell | 2 | 2017 | 73 | 0.530 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2019 | 206 | 0.520 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2015 | 221 | 0.460 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 1573 | 0.460 |
Why?
| | Dose-Response Relationship, Drug | 13 | 2021 | 1945 | 0.420 |
Why?
| | Depsipeptides | 1 | 2012 | 13 | 0.410 |
Why?
| | Quinazolines | 2 | 2011 | 243 | 0.400 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2012 | 42 | 0.390 |
Why?
| | Pyrazoles | 2 | 2013 | 405 | 0.380 |
Why?
| | Area Under Curve | 8 | 2021 | 282 | 0.370 |
Why?
| | Sirolimus | 1 | 2012 | 189 | 0.370 |
Why?
| | Neuroendocrine Tumors | 1 | 2012 | 99 | 0.360 |
Why?
| | Sulindac | 2 | 2008 | 15 | 0.360 |
Why?
| | Nitriles | 2 | 2008 | 161 | 0.360 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 421 | 0.340 |
Why?
| | Aged | 30 | 2024 | 22089 | 0.340 |
Why?
| | Skin Neoplasms | 2 | 2017 | 833 | 0.330 |
Why?
| | Middle Aged | 33 | 2024 | 31079 | 0.330 |
Why?
| | Tosyl Compounds | 1 | 2008 | 16 | 0.310 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 52 | 0.300 |
Why?
| | Drug Dosage Calculations | 1 | 2008 | 20 | 0.290 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 1046 | 0.290 |
Why?
| | Bone Density Conservation Agents | 1 | 2008 | 73 | 0.290 |
Why?
| | Liver Failure, Acute | 1 | 2008 | 63 | 0.290 |
Why?
| | Androgen Antagonists | 1 | 2008 | 79 | 0.290 |
Why?
| | Breast Neoplasms | 3 | 2023 | 2150 | 0.270 |
Why?
| | Food | 1 | 2008 | 155 | 0.270 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7065 | 0.260 |
Why?
| | Fasting | 1 | 2008 | 264 | 0.260 |
Why?
| | Pain | 3 | 2011 | 760 | 0.260 |
Why?
| | Humans | 50 | 2024 | 129126 | 0.250 |
Why?
| | Liver Diseases | 2 | 2019 | 285 | 0.250 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 774 | 0.250 |
Why?
| | Osteoporosis | 1 | 2008 | 233 | 0.240 |
Why?
| | Administration, Oral | 5 | 2012 | 759 | 0.240 |
Why?
| | Professional Role | 2 | 2017 | 161 | 0.240 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.240 |
Why?
| | Deoxycytidine | 5 | 2011 | 164 | 0.240 |
Why?
| | Female | 34 | 2024 | 68517 | 0.230 |
Why?
| | Pancreatic Neoplasms | 1 | 2012 | 878 | 0.230 |
Why?
| | Platinum | 1 | 2024 | 44 | 0.230 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1359 | 0.230 |
Why?
| | Maximum Tolerated Dose | 10 | 2020 | 194 | 0.230 |
Why?
| | Medical Oncology | 2 | 2017 | 274 | 0.220 |
Why?
| | Hedgehog Proteins | 2 | 2017 | 187 | 0.220 |
Why?
| | Nausea | 4 | 2020 | 108 | 0.220 |
Why?
| | Midazolam | 1 | 2024 | 48 | 0.220 |
Why?
| | Adult | 27 | 2024 | 35512 | 0.220 |
Why?
| | Male | 33 | 2024 | 63201 | 0.220 |
Why?
| | Lung Neoplasms | 2 | 2015 | 2329 | 0.220 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2024 | 66 | 0.220 |
Why?
| | Angiogenesis Inhibitors | 4 | 2010 | 216 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2017 | 764 | 0.210 |
Why?
| | Vomiting | 3 | 2020 | 128 | 0.200 |
Why?
| | Cohort Studies | 5 | 2020 | 5407 | 0.180 |
Why?
| | Lymphoma | 2 | 2016 | 194 | 0.180 |
Why?
| | Sulfonamides | 2 | 2019 | 500 | 0.180 |
Why?
| | ErbB Receptors | 2 | 2017 | 603 | 0.180 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2023 | 191 | 0.180 |
Why?
| | Pyrimidines | 2 | 2024 | 445 | 0.180 |
Why?
| | Prostatic Neoplasms | 1 | 2008 | 1013 | 0.180 |
Why?
| | Apoptosis | 3 | 2008 | 2438 | 0.180 |
Why?
| | Trastuzumab | 2 | 2023 | 100 | 0.180 |
Why?
| | Fluorouracil | 4 | 2011 | 197 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 19 | 0.170 |
Why?
| | Drug Evaluation | 1 | 2020 | 81 | 0.170 |
Why?
| | Analgesics, Opioid | 1 | 2008 | 908 | 0.170 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1275 | 0.170 |
Why?
| | Azepines | 1 | 2020 | 88 | 0.170 |
Why?
| | Hydroxamic Acids | 1 | 2019 | 88 | 0.160 |
Why?
| | TWEAK Receptor | 1 | 2017 | 5 | 0.150 |
Why?
| | Models, Biological | 1 | 2024 | 1695 | 0.140 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 35 | 0.140 |
Why?
| | Hematology | 1 | 2017 | 14 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 501 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2020 | 479 | 0.140 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 54 | 0.130 |
Why?
| | Pharmaceutical Services | 1 | 2017 | 83 | 0.130 |
Why?
| | Pain Management | 2 | 2017 | 320 | 0.130 |
Why?
| | Maytansine | 1 | 2016 | 16 | 0.130 |
Why?
| | Aminoglycosides | 1 | 2016 | 21 | 0.130 |
Why?
| | Specialty Boards | 1 | 2016 | 33 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2739 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 313 | 0.120 |
Why?
| | Drugs, Investigational | 1 | 2015 | 32 | 0.120 |
Why?
| | Biomarkers, Tumor | 4 | 2010 | 1185 | 0.120 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 89 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 421 | 0.120 |
Why?
| | Prescription Drugs | 1 | 2016 | 116 | 0.120 |
Why?
| | American Heart Association | 1 | 2016 | 309 | 0.120 |
Why?
| | Carbazoles | 1 | 2015 | 84 | 0.120 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2014 | 18 | 0.110 |
Why?
| | Insurance Claim Review | 1 | 2014 | 72 | 0.110 |
Why?
| | Drug Administration Schedule | 5 | 2019 | 758 | 0.110 |
Why?
| | Carboplatin | 3 | 2009 | 140 | 0.110 |
Why?
| | Chronic Pain | 1 | 2017 | 254 | 0.100 |
Why?
| | Specialization | 1 | 2014 | 144 | 0.100 |
Why?
| | Gonanes | 1 | 2012 | 27 | 0.100 |
Why?
| | Everolimus | 1 | 2012 | 68 | 0.100 |
Why?
| | Signal Transduction | 2 | 2017 | 4838 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 343 | 0.100 |
Why?
| | Biomarkers | 3 | 2018 | 3896 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1000 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2013 | 184 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 1 | 2011 | 68 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 109 | 0.090 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 239 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 811 | 0.090 |
Why?
| | Phytotherapy | 1 | 2011 | 76 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2020 | 14571 | 0.090 |
Why?
| | Curriculum | 1 | 2017 | 925 | 0.090 |
Why?
| | Glucuronidase | 2 | 2008 | 43 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2015 | 768 | 0.090 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 490 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 41 | 0.080 |
Why?
| | Kidney | 1 | 2017 | 1308 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2011 | 480 | 0.080 |
Why?
| | Treatment Outcome | 7 | 2015 | 10226 | 0.080 |
Why?
| | Oligosaccharides | 2 | 2008 | 57 | 0.080 |
Why?
| | Clinical Competence | 1 | 2017 | 1021 | 0.080 |
Why?
| | Cannabinoids | 1 | 2011 | 132 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 81 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 380 | 0.080 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 29 | 0.080 |
Why?
| | Primary Health Care | 2 | 2017 | 1641 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2347 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 592 | 0.080 |
Why?
| | Capecitabine | 4 | 2011 | 47 | 0.080 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2008 | 4 | 0.080 |
Why?
| | Equipment and Supplies | 1 | 2008 | 41 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1493 | 0.080 |
Why?
| | Taxoids | 2 | 2008 | 95 | 0.080 |
Why?
| | Boronic Acids | 1 | 2008 | 37 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 107 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 67 | 0.070 |
Why?
| | Marijuana Smoking | 1 | 2011 | 239 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2008 | 47 | 0.070 |
Why?
| | Etoposide | 1 | 2008 | 150 | 0.070 |
Why?
| | Farnesyltranstransferase | 1 | 2007 | 35 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 79 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 291 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2010 | 250 | 0.070 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 60 | 0.070 |
Why?
| | Reference Standards | 1 | 2008 | 170 | 0.070 |
Why?
| | Receptors, Vitronectin | 1 | 2007 | 9 | 0.070 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 123 | 0.070 |
Why?
| | Integrin alphaVbeta3 | 1 | 2007 | 19 | 0.070 |
Why?
| | Snake Venoms | 1 | 2007 | 21 | 0.070 |
Why?
| | Absorptiometry, Photon | 1 | 2008 | 251 | 0.070 |
Why?
| | Benzamides | 1 | 2008 | 195 | 0.070 |
Why?
| | Pyrazines | 1 | 2008 | 88 | 0.070 |
Why?
| | Oxycodone | 1 | 2008 | 49 | 0.070 |
Why?
| | Indoles | 2 | 2008 | 372 | 0.070 |
Why?
| | Fatigue | 4 | 2012 | 320 | 0.070 |
Why?
| | Fentanyl | 1 | 2008 | 80 | 0.070 |
Why?
| | Triazoles | 1 | 2008 | 152 | 0.070 |
Why?
| | Animals | 6 | 2020 | 34600 | 0.070 |
Why?
| | Palliative Care | 2 | 2011 | 721 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2010 | 347 | 0.070 |
Why?
| | Delayed-Action Preparations | 1 | 2008 | 176 | 0.070 |
Why?
| | Morphine | 1 | 2008 | 129 | 0.070 |
Why?
| | Integrins | 1 | 2007 | 92 | 0.070 |
Why?
| | Methadone | 1 | 2008 | 90 | 0.070 |
Why?
| | Young Adult | 3 | 2020 | 12389 | 0.070 |
Why?
| | Pharmacogenetics | 1 | 2008 | 171 | 0.070 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2007 | 113 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 3184 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 475 | 0.070 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 103 | 0.070 |
Why?
| | Alkyl and Aryl Transferases | 1 | 2006 | 53 | 0.070 |
Why?
| | Thiophenes | 1 | 2007 | 119 | 0.070 |
Why?
| | Societies, Pharmaceutical | 2 | 2017 | 25 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 9768 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 475 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 451 | 0.060 |
Why?
| | Protein Binding | 1 | 2011 | 2106 | 0.060 |
Why?
| | Granisetron | 1 | 2024 | 5 | 0.060 |
Why?
| | Quinuclidines | 1 | 2024 | 9 | 0.060 |
Why?
| | Ondansetron | 1 | 2024 | 15 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 813 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1243 | 0.060 |
Why?
| | United States | 5 | 2017 | 13939 | 0.060 |
Why?
| | Isoquinolines | 1 | 2024 | 42 | 0.060 |
Why?
| | Occupational Exposure | 1 | 2008 | 311 | 0.060 |
Why?
| | Quinolones | 1 | 2006 | 127 | 0.060 |
Why?
| | Cannabis | 1 | 2011 | 436 | 0.060 |
Why?
| | Infusions, Intravenous | 2 | 2019 | 385 | 0.060 |
Why?
| | RNA, Catalytic | 1 | 2005 | 185 | 0.060 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 682 | 0.060 |
Why?
| | Prospective Studies | 3 | 2024 | 7079 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 750 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 2024 | 0.050 |
Why?
| | Camptothecin | 1 | 2023 | 107 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 192 | 0.050 |
Why?
| | Heart Failure | 1 | 2016 | 2158 | 0.050 |
Why?
| | Diarrhea | 2 | 2015 | 177 | 0.050 |
Why?
| | Adolescent | 2 | 2020 | 20301 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1363 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 336 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1293 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 55 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 58 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 115 | 0.040 |
Why?
| | Neutropenia | 2 | 2009 | 136 | 0.040 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.040 |
Why?
| | Glutathione S-Transferase pi | 1 | 2017 | 9 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2017 | 36 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2018 | 291 | 0.040 |
Why?
| | Anemia | 2 | 2009 | 161 | 0.040 |
Why?
| | Partial Thromboplastin Time | 2 | 2008 | 49 | 0.030 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 26 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 5070 | 0.030 |
Why?
| | Amidine-Lyases | 1 | 1997 | 1 | 0.030 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2007 | 25 | 0.030 |
Why?
| | Mixed Function Oxygenases | 1 | 1997 | 37 | 0.030 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1997 | 51 | 0.030 |
Why?
| | Multienzyme Complexes | 1 | 1997 | 69 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 145 | 0.030 |
Why?
| | Paclitaxel | 2 | 2009 | 215 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2017 | 129 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 5377 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 984 | 0.030 |
Why?
| | Cardiotoxins | 1 | 2015 | 4 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2015 | 26 | 0.030 |
Why?
| | Analgesics | 1 | 1997 | 166 | 0.030 |
Why?
| | Mucositis | 1 | 2015 | 19 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 348 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 136 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4915 | 0.030 |
Why?
| | Pharmacy Residencies | 1 | 2014 | 12 | 0.030 |
Why?
| | Drug Discovery | 1 | 2015 | 130 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1671 | 0.030 |
Why?
| | Students, Pharmacy | 1 | 2014 | 113 | 0.030 |
Why?
| | Stroke Volume | 1 | 2015 | 590 | 0.020 |
Why?
| | Electrocardiography | 1 | 2015 | 607 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2016 | 506 | 0.020 |
Why?
| | Dioxoles | 1 | 2011 | 9 | 0.020 |
Why?
| | Tetrahydroisoquinolines | 1 | 2011 | 8 | 0.020 |
Why?
| | Biological Availability | 1 | 2011 | 123 | 0.020 |
Why?
| | Mice | 3 | 2020 | 16644 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3342 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 357 | 0.020 |
Why?
| | Massage | 1 | 2010 | 43 | 0.020 |
Why?
| | Alopecia | 1 | 2009 | 28 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3788 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 66 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2014 | 608 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 39 | 0.020 |
Why?
| | Bortezomib | 1 | 2008 | 45 | 0.020 |
Why?
| | Maximum Allowable Concentration | 1 | 2008 | 14 | 0.020 |
Why?
| | Floxuridine | 1 | 2008 | 5 | 0.020 |
Why?
| | Protein Kinase C beta | 1 | 2008 | 21 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2010 | 261 | 0.020 |
Why?
| | Platelet Factor 4 | 1 | 2008 | 32 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2008 | 85 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2007 | 120 | 0.020 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2007 | 15 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2008 | 120 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2007 | 55 | 0.020 |
Why?
| | Protein Prenylation | 1 | 2006 | 34 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2006 | 27 | 0.020 |
Why?
| | Carcinoid Tumor | 1 | 2006 | 24 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2008 | 253 | 0.020 |
Why?
| | Heparin | 1 | 2008 | 240 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2008 | 182 | 0.020 |
Why?
| | Cell Adhesion Molecules | 1 | 2007 | 172 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 90 | 0.020 |
Why?
| | Risk | 1 | 2008 | 856 | 0.020 |
Why?
| | Inflammation | 1 | 1997 | 2668 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 197 | 0.020 |
Why?
| | Fibroblast Growth Factors | 1 | 2006 | 171 | 0.020 |
Why?
| | Antibody Formation | 1 | 2006 | 288 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 89 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1209 | 0.010 |
Why?
| | Monocytes | 1 | 2008 | 543 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2613 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 180 | 0.010 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 256 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 186 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1687 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2004 | 184 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1462 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2007 | 701 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3700 | 0.010 |
Why?
| | Melanoma | 1 | 2006 | 752 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2006 | 753 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3383 | 0.010 |
Why?
| | Carrageenan | 1 | 1997 | 8 | 0.010 |
Why?
| | Lyases | 1 | 1997 | 9 | 0.010 |
Why?
| | Bradykinin | 1 | 1997 | 45 | 0.010 |
Why?
| | Substance P | 1 | 1997 | 43 | 0.010 |
Why?
| | Edema | 1 | 1997 | 125 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1997 | 367 | 0.010 |
Why?
| | Serotonin | 1 | 1997 | 318 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6518 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1617 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1997 | 2041 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1997 | 2245 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5173 | 0.000 |
Why?
|
|
O'Bryant's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|